Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.-Reference-Cited by-同舟云学术

Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:5027-5027
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Sweeney Christopher¹,Gray Kathryn P.¹,Harshman Lauren Christine¹,Elfiky Aymen²,Choueiri Toni K.¹,Pomerantz Mark¹,Dumas Kathryn³,Fredericks Amanda³,Taplin Mary-Ellen¹,Kantoff Philip W.¹

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA

2. Dana-Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Boston, MA

3. Dana-Farber Cancer Center Institute, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.5027

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review;Therapeutic Advances in Medical Oncology;2022-01

2. Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways;Cancer Drug Resistance;2020

3. Targeting Androgen/Estrogen Receptors Crosstalk in Cancer;Trends in Cancer;2016-01

4. New advances in genitourinary cancer: evidence gathered in 2014;Cancer and Metastasis Reviews;2015-07-31

5. Optimal sequence of bone target drugs in metastatic prostatic cancer;Expert Review of Anticancer Therapy;2015-06-12